|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 34.77 USD | -2.50% |
|
-8.91% | +28.02% |
| 07-22 | Celldex Therapeutics, Inc. - Special Call | |
| 07-22 | Celldex's Phase 3 Barzolvolimab Study in Chronic Spontaneous Urticaria in Focus After Prurigo Nodularis Exit, Morgan Stanley Says | MT |
| Market Cap | 2.8B 2.45B 2.28B 2.09B 3.94B 270B 4B 27.12B 10.61B 132B 10.51B 10.28B 456B | P/E 2026 * |
-8.22x | P/E 2027 * | -8.22x |
|---|---|---|---|---|---|
| Enterprise Value | 2.21B 1.94B 1.8B 1.66B 3.12B 214B 3.17B 21.46B 8.39B 105B 8.31B 8.14B 361B | EV / Sales 2026 * |
917x | EV / Sales 2027 * | 207x |
| Free-Float |
99.73% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Celldex Therapeutics, Inc.
| 1 day | -2.50% | ||
| 1 week | -8.91% | ||
| Current month | -6.56% | ||
| 1 month | +7.22% | ||
| 3 months | +1.52% | ||
| 6 months | +32.86% | ||
| Current year | +28.02% |
| 1 week | 33.37 |  | 37.94 |
| 1 month | 32.57 | | 40.3 |
| Current year | 22.33 | | 40.3 |
| 1 year | 19.72 | | 40.3 |
| 3 years | 14.4 | | 53.18 |
| 5 years | 14.4 | | 57.2 |
| 10 years | 1.5 | | 75.3 |
| Manager | Title | Age | Since |
|---|---|---|---|
Tibor Keler
CTO | Chief Tech/Sci/R&D Officer | 67 | 2014-07-29 |
Anthony Marucci
CEO | Chief Executive Officer | 64 | 2008-08-31 |
Sam Martin
DFI | Director of Finance/CFO | 55 | 2009-03-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Anthony Marucci
BRD | Director/Board Member | 64 | 2008-11-30 |
Harry Penner
CHM | Chairman | 80 | 2025-06-04 |
Herbert Conrad
BRD | Director/Board Member | 93 | 2008-02-29 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 6/25/26 | Free | Chief Financial Officer | 93,000 | 0.1185% | ||
| 6/25/26 | Free | Director | 26,000 | 0.0331% | ||
| 6/25/26 | Free | Director | 26,000 | 0.0331% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.50% | -8.91% | +57.62% | -4.50% | 2.8B | |
| -4.89% | -7.90% | -4.49% | +9.27% | 48.5B | |
| -0.14% | -1.05% | +376.39% | +583.71% | 38.97B | |
| +0.39% | +4.36% | +9.59% | +61.99% | 35.43B | |
| -1.54% | -4.48% | +24.89% | -13.03% | 33.65B | |
| -0.87% | -1.56% | -1.43% | +29.16% | 26.58B | |
| -1.28% | -5.14% | - | - | 16.82B | |
| -0.67% | -1.50% | +70.98% | +115.31% | 15.18B | |
| +1.32% | +2.29% | +14.62% | +15.52% | 13.89B | |
| +0.40% | -0.41% | +19.80% | -31.98% | 12.76B | |
| Average | +0.83% | -1.74% | +63.11% | +85.05% | 24.46B | |
| Weighted average by Cap. | -0.18% | -1.34% | +75.88% | +119.75% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 2.42M 2.12M 1.97M 1.81M 3.4M 233M 3.46M 23.41M 9.16M 114M 9.07M 8.88M 394M | 11.04M 9.68M 8.99M 8.26M 15.56M 1.07B 15.8M 107M 41.85M 521M 41.44M 40.56M 1.8B |
| Net income | -330M -289M -269M -247M -465M -31.87B -472M -3.2B -1.25B -15.57B -1.24B -1.21B -53.82B | -367M -322M -299M -275M -518M -35.48B -526M -3.56B -1.39B -17.34B -1.38B -1.35B -59.92B |
| Net Debt | -584M -512M -476M -437M -823M -56.4B -836M -5.66B -2.21B -27.56B -2.19B -2.15B -95.25B | -515M -452M -420M -385M -726M -49.73B -737M -4.99B -1.95B -24.31B -1.93B -1.89B -83.99B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-22 | US$34.77 | -2.50% | 1,928,156 |
| 26-07-21 | US$35.66 | +0.68% | 1,392,017 |
| 26-07-20 | US$35.42 | +0.20% | 527,637 |
| 26-07-17 | US$35.35 | -0.14% | 1,149,060 |
| 26-07-16 | US$35.40 | -7.60% | 954,885 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CLDX Stock
Select your edition
All financial news and data tailored to specific country editions
